GLP-1s Protect Against Stroke, Alzheimer's Disease
A large-scale Mendelian randomisation study suggests that GLP-1 receptor agonists, commonly used for diabetes and obesity, may offer protective benefits against stroke and Alzheimer's disease. The findings were consistent across European, East Asian, and African ancestry groups.
Why it matters
This research suggests potential new therapeutic applications for existing drugs, which could significantly impact neurological healthcare.
GENETIC evidence has suggested that glucagon-like peptide-1 receptor agonists (GLP-1RAs) may protect against Alzheimer’s disease and stroke, particularly ischaemic and cardioembolic subtypes, according to a new Mendelian randomisation study examining associations across multiple ancestry groups.
GLP-1RAs are widely used to treat type 2 diabetes (T2D) and obesity and have demonstrated cardiovascular benefits. Growing interest in their potential effects on brain health has prompted researchers to investigate whether these benefits could extend to neurological conditions. However, whether genetically proxied GLP-1RA effects are associated with a lower risk of stroke and Alzheimer’s disease across different ancestries has remained unclear.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in